Neu REFIX beta glucans improving Multiple Sclerosis patients’ gut microbiome awarded as the best poster
Nichi BRITE Beta glucans yileding clinically encouraging outcome in a trial was presented in the webinar that commemorated World Parkinsons Day held on the 10th April 2023
Neurology Live, a clinical neurologists focused media portal has published GN Corporation’s presentation at the MDA on the Clinical trial results of Neu REFIX in Duchenne Muscular Dystrophy
GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its
NICHI BRITE (AFO-202), one of the NICHI GLUCAN brand products for overseas markets, has undergone clinical tri
GNC’s activities are introduced in the Japan Cabinet Office’s site ‘Invest Japan’
This is the research on the potential of beta-glucan for autism
A breakthrough achievement on miRNA140 is published in Medicine Innovates
An interview was published in a feature story in Bloomburg
Japanese scientists, research collaborators to Nichi-in Centre for Regenerative Medicine
Neu REFIX B-glucans improve Anti-aging Butyrate & gut microbiome
Manuscript published in Stem Cell Reviews and Reports
